Irene Abramovich
Psychiatry · West Hartford, CTNPI 1407864887
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $256,474 of the $351,706 with a category attached, or 72.9%. 15 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 29.8% of the total. Among psychiatry clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 774 payments — averaging $454.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$105K
- Alkermes, Inc.$53K
- Supernus Pharmaceuticals, Inc.$52K
- Teva Pharmaceuticals USA, Inc.$43K
- Axsome Therapeutics, Inc.$35K
- E.r. Squibb & Sons, L.L.C.$30K
- plus $34K from 9 others
What the payments were for
- Consulting fees$46,80513%
- Speaking & faculty fees$256,47473%
- Travel & lodging$32,9979%
- Food & beverage$15,2384%
- Education$1920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 192 | $104,818 |
| Alkermes, Inc. | 109 | $53,258 |
| Supernus Pharmaceuticals, Inc. | 90 | $51,544 |
| Teva Pharmaceuticals USA, Inc. | 50 | $43,054 |
| Axsome Therapeutics, Inc. | 42 | $34,545 |
| E.r. Squibb & Sons, L.L.C. | 35 | $30,433 |
| Neurocrine Biosciences, Inc. | 34 | $21,707 |
| AbbVie(2 entities) | 123 | $8,677 |
| Idorsia Pharmaceuticals US Inc | 2 | $2,030 |
| Jazz Pharmaceuticals Inc. | 1 | $800 |
| Lundbeck LLC | 57 | $581 |
| Sunovion Pharmaceuticals Inc. | 35 | $166 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $47 |
| Tris Pharma Inc | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$207,108
- ABILIFY MAINTENA$58,780
- ARISTADA INITIO$51,777
- QELBREE$48,028
- REXULTI$46,286
- UZEDY$37,626
- Auvelity$34,054
- INGREZZA$21,363
- ABILIFY ASIMTUFII$9,349
- COBENFY$7,742
- VRAYLAR$7,479
- AUSTEDO$3,679
- QUVIVIQ$2,030
- SUNOSI$800
How this compares
$351,706 in reported general payments places this provider in the 95th percentile of 644 psychiatry providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 24 | $211,788 |
| RexultiBrexpiprazole | 81 | $117,486 |
| Abilify MaintenaAripiprazole | 38 | $106,336 |
| VraylarCariprazine Hcl | 69 | $101,685 |
| CaplytaLumateperone Tosylate | 29 | $50,969 |
| TrintellixVortioxetine Hydrobromide | 85 | $50,206 |
| AristadaAripiprazole Lauroxil | 19 | $29,959 |
| LamictalLamotrigine | 30 | $27,377 |
| QuviviqDaridorexant Hcl | 24 | $11,809 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $10,990 |
| BelsomraSuvorexant | 26 | $10,935 |
| VyvanseLisdexamfetamine Dimesylate | 16 | $8,930 |
| Lurasidone Hcl | 32 | $8,539 |
| QelbreeViloxazine Hcl | 15 | $8,473 |
| Divalproex Sodium | 95 | $6,812 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $104,818 | $223,822119 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $21,707 | $211,78824 claims |
| AbbVieVraylar | $8,677 | $101,68569 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $15 | $59,136101 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $47 | $50,96929 claims |
| Alkermes, Inc.Aristada | $53,258 | $29,95919 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $2,030 | $11,80924 claims |
| Axsome Therapeutics, Inc.Auvelity | $34,545 | $10,99011 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $51,544 | $8,47315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 644 psychiatry providers in Connecticut.
Other psychiatry in West Hartford
- John NazarianWest Hartford$79K
- Dale WallingtonWest Hartford$31K
- Vladimir CoricNew Haven$133.7M
- Donald AmmermanDanbury$1.5M
- Joseph GoldbergNew Canaan$914K
- Lisa HardingMilford$608K
- Tarique PereraDanbury$383K
- John GelinasDanbury$364K
- Robert BermanNew Haven$126K
- John KrystalWest Haven$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.